Johnson & Johnson (JNJ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT (amivantamab for injection) in ...

A judge has dismissed New York City's lawsuit seeking to hold Exxon Mobil , BP and Shell liable for misleading the public ...

New York court dismisses NYC lawsuit against Exxon, BP, and Shell over climate change deception claims, citing lack of proof of greenwashing.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

This latest approval for Orpathys in NSCLC makes the drug available in both the first- and second-line settings.

ORIC Pharmaceuticals (ORIC) announced that the company has entered into a supply agreement with Janssen Research & ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS® (savolitinib) has been granted approval by the China National Medical Products ...

Chinese biopharma Hutchmed today announced that the supplemental New Drug Application for Orpathys (savolitinib) has been ...

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and ...

Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...